Uterine polyp. Polyp of corpus uteri
Conditions
Interventions
Intervention 1: Intervention group: Patients in this group received Medroxyprogesterone acetate 10 mg tablets (manufactured by Iran Hormone Company or equivalent product approved by the Ministry of He
Sponsors
Esfahan University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: Age 18 to 45 years Confirmed uterine polyp on transvaginal ultrasound Willingness to provide informed consent
Exclusion criteria
Exclusion criteria: Menopause Hypersensitivity to medroxyprogesterone Presence of intrauterine device (IUD) History of uterine diseases, tumors, or malignancies Hepatic or renal failure Pregnancy or lactation History of breast cancer Acute infection
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Uterine polyp size. Timepoint: at baseline and three months after intervention. Method of measurement: millimeters – transvaginal ultrasound.;Endometrial thickness. Timepoint: at baseline and three months after intervention. Method of measurement: millimeters – transvaginal ultrasound.;Presence and severity of clinical symptoms including spotting and menorrhagia. Timepoint: at baseline and three months after intervention. Method of measurement: patient reported. | — |
Secondary
| Measure | Time frame |
|---|---|
| Body Mass Index. Timepoint: at baseline and three months after intervention. Method of measurement: kg/m² – from patient records.;Weight changes. Timepoint: at baseline and three months after intervention. Method of measurement: kg – from patient records.;Occurrence of adverse effects of medication such as dizziness, nausea, and loss of appetite. Timepoint: during the three-month follow-up. Method of measurement: patient reported. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactTahereh Khalili Borujeni
Esfahan University of Medical Sciences
Outcome results
None listed